Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Thank you, Victoria, and good afternoon, everyone. We entered the year determined solidify FILSPARI’s foundational positioning in IgA nephropathy, unlock additional growth for FILSPARI through a ...

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing ...

The UK’s MHRA also converts the conditional approval of FILSPARI to standard approval Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European ...

“As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the ...

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...

“The European Commission’s standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe,” said Jula Inrig, M.D., chief medical officer of ...

We look forward to continuing working closely with healthcare professionals, patient communities, and regulatory bodies to ensure access to FILSPARI across Europe." The European Commission's ...